"Company","Current Parent Company","Parent at the Time of the Penalty Announcement","Recap of Ownership Changes","Penalty Amount","Subtraction From Penalty Amount to Avoid Double Counting","Penalty Amount Adjusted For Eliminating Multiple Counting","Penalty Year","Penalty Date","Offense Group","Primary Offense","Secondary Offense","Description","Level of Government","Action Type","Agency","Civil/Criminal","Prosecution Agreement","Court","Case ID","Private Litigation Case Title","Lawsuit Resolution","Original System ID","Facility Name","Facility Address","Facility City","Facility State","Facility Zip","Facility County","NAICS Code","NAICS Translation","Current Parent HQ Country","Current Parent HQ State","Current Parent Ownership Structure","Current Parent Stock Ticker","Current Parent ISIN","Current Parent Major Industry","Current Parent Specific Industry","Info Source","PACER Link","Notes"
"Abbott Laboratories Inc.","AbbVie","Abbott Laboratories","Abbott spun off AbbVie in 2013","$1,500,000,000","$0","$1,500,000,000","2012","20120507","healthcare-related offenses","off-label or unapproved promotion of medical products","","Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company's unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","USA","Illinois","publicly traded","ABBV","US00287Y1091","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote","",""
"Advanced Sterilization Products, a division of Ethicon Inc.","Johnson & Johnson","Johnson & Johnson","","$1,200,000","$0","$1,200,000","2013","20131204","safety-related offenses","drug or medical equipment safety violation","","Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP's executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.","federal","agency action","Food and Drug Administration","civil","","","","","","","","","Irvine","California","","","","","USA","New Jersey","publicly traded","JNJ","US4781601046","pharmaceuticals","pharmaceuticals","http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm","",""
"Allergan Inc.","AbbVie","Allergan Inc.","Allergan merged with Actavis and both were bought by AbbVie in 2020","$600,000,000","$0","$600,000,000","2010","20100901","healthcare-related offenses","off-label or unapproved promotion of medical products","","American pharmaceutical manufacturer Allergan Inc. has agreed to plead guilty and pay $600 million to resolve its criminal and civil liability arising from the company's unlawful promotion of its biological product, Botox Therapeutic, for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a criminal fine and forfeiture totaling $375 million and a civil settlement with the federal government and the states of $225 million.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","USA","Illinois","publicly traded","ABBV","US00287Y1091","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/allergan-agrees-plead-guilty-and-pay-600-million-resolve-allegations-label-promotion-botox","",""
"Amgen Inc.","Amgen","Amgen","","$762,000,000","$0","$762,000,000","2012","20121219","healthcare-related offenses","off-label or unapproved promotion of medical products","","U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by American biotechnology giant Amgen Inc. for illegally introducing a misbranded drug into interstate commerce. The plea is part of a global settlement with the United States in which Amgen agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of certain drugs.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","USA","California","publicly traded","AMGN","US0311621009","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/amgen-inc-pleads-guilty-federal-charge-brooklyn-ny-pays-762-million-resolve-criminal","",""
"AstraZeneca LP","AstraZeneca","AstraZeneca","","$520,000,000","$0","$520,000,000","2010","20100427","healthcare-related offenses","off-label or unapproved promotion of medical products","","AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration, the Departments of Justice and Health and Human Services' Health Care Fraud Enforcement Action Team.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil","","","","","","","","","","","","","","","United Kingdom","","publicly traded","LSE: AZN","GB0009895292","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing","",""
"Atricure Inc.","AtriCure","AtriCure","","$3,760,000","$0","$3,760,000","2010","20100202","healthcare-related offenses","off-label or unapproved promotion of medical products","","Atricure Inc., a medical device manufacturer, agreed to pay the United States $3.76 million to resolve civil claims in connection with the promotion of its surgical ablation devices.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil","","","","","","","","","","","","","","","USA","Ohio","publicly traded","ATRC","US04963C2098","medical equipment and supplies","medical devices","https://www.justice.gov/opa/pr/atricure-pay-us-376-million-resolve-medicare-fraud-allegations","",""
"B. Braun Medical Inc.","B. Braun Melsungen","B. Braun Melsungen","","$7,800,000","$0","$7,800,000","2016","20160518","safety-related offenses","drug or medical equipment safety violation","","Drug and medical device company B. Braun Medical Inc. agreed to pay $4.8 million in penalties and forfeiture and up to an additional $3 million in restitution to resolve its criminal liability for selling contaminated B. Braun pre-filled saline flush syringes in 2007.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","non-prosecution agreement","","","","","","","","","","","","","","Germany","","privately held","","","medical equipment and supplies","medical supplies","https://www.justice.gov/opa/pr/b-braun-medical-inc-agrees-resolve-criminal-liability-relating-its-sale-contaminated-syringes","",""
"Boehringer Ingelheim Pharmaceuticals Inc.","Boehringer Ingelheim","Boehringer Ingelheim","","$95,000,000","$0","$95,000,000","2012","20121025","healthcare-related offenses","off-label or unapproved promotion of medical products","","Boehringer Ingelheim Pharmaceuticals Inc. agreed to pay $95 million to resolve allegations relating to the improper promotion of the stroke-prevention drug Aggrenox, the chronic obstructive pulmonary disease drugs Atrovent and Combivent, and the hypertension drug Micardis.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil","","","","","","","","","","","","","","","Germany","","privately held","","","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/boehringer-ingelheim-pay-95-million-resolve-false-claims-act-allegations","",""
"Boston Scientific Corp.","Boston Scientific Corp.","Boston Scientific Corp.","","$30,000,000","$0","$30,000,000","2013","20131017","safety-related offenses","drug or medical equipment safety violation","","Boston Scientific Corp. and its subsidiaries, Guidant LLC, Guidant Sales LLC and Cardiac Pacemakers Inc. (Guidant), have agreed to pay $30 million to settle allegations that, between 2002 and 2005, Guidant knowingly sold defective heart devices to health care facilities that in turn implanted the devices into Medicare patients, the Justice Department announced. Boston Scientific acquired Guidant, a medical device manufacturer, in 2006.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil","","","","","","","","","","","","","","","USA","Massachusetts","publicly traded","BSX","US1011371077","medical equipment and supplies","medical devices","http://www.justice.gov/opa/pr/boston-scientific-and-subsidiaries-pay-30-million-guidant-s-sale-defective-heart-devices-use","",""
"CareFusion Corp.","Becton Dickinson","CareFusion Corp.","Becton Dickinson acquired CareFusion Corp in 2015","$40,100,000","$0","$40,100,000","2014","20140109","government-contracting-related offenses","False Claims Act and related","off-label or unapproved promotion of medical products","CareFusion Corp. agreed to pay the government $40.1 million to settle allegations that it violated the False Claims Act by paying kickbacks and promoting its products for uses that were not approved by the Food and Drug Administration.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil","","","","","","","","","","","","","","","USA","New Jersey","publicly traded","BDX","US0758871091","medical equipment and supplies","medical supplies","https://www.justice.gov/opa/pr/carefusion-pay-government-401-million-resolve-allegations-include-more-11-million-kickbacks","",""
"Cell Therapeutics Inc.","","","","$10,500,000","$0","$10,500,000","2007","20070417","healthcare-related offenses","off-label or unapproved promotion of medical products","kickbacks and bribery","Cell Therapeutics Inc. has agreed to pay the United States $10.5 million to resolve allegations of the company's improper marketing of the anti-cancer prescription drug Trisenox. According to the government's complaint, CTI promoted the drug for various uses that were unapproved by the Food & Drug Administration.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","","","","","","","","","","","https://www.justice.gov/archive/opa/pr/2007/April/07_civ_258.html","",""
"Cephalon Inc","Teva Pharmaceutical Industries","Cephalon Inc.","Teva bought Cephalon in 2011","$425,000,000","$0","$425,000,000","2008","20080929","healthcare-related offenses","off-label or unapproved promotion of medical products","False Claims Act and related","Cephalon Inc. agreed to enter a criminal plea and pay a $50 million criminal penalty and a $375 million civil settlement to resolve claims that it marketed three drugs for uses not approved by the Food and Drug Administration.","federal","agency action","Justice Department Civil Division","civil and criminal","","","","","","","","","","","","","","","Israel","","publicly traded","TEVA","IL0006290147","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/opa/pr/2008/September/08-civ-860.html","",""
"ConAgra Grocery Products LLC","ConAgra Brands","ConAgra Brands","","$11,200,000","$0","$11,200,000","2015","20150520","safety-related offenses","food safety violation","","ConAgra Grocery Products LLC, a subsidiary of ConAgra Foods Inc., agreed to plead guilty and pay $11.2 million -- an $8 million criminal fine and $3.2 million in forfeiture of assets -- in connection with the shipment of contaminated peanut butter linked to a 2006 through 2007 nationwide outbreak of salmonella poisoning.","federal","agency action","Food and Drug Administration referral to the Justice Department","criminal","","","","","","","","","","","","","","","USA","Nebraska","publicly traded","CAG","US2058871029","food products","food products","http://www.justice.gov/opa/pr/conagra-subsidiary-agrees-enter-guilty-plea-connection-2006-through-2007-outbreak-salmonella","",""
"Cypress Pharmaceutical Inc.","Currax Pharmaceuticals","Pernix Therapeutics","Currax bought Pernix in 2019","$2,800,000","$0","$2,800,000","2012","20120328","healthcare-related offenses","off-label or unapproved promotion of medical products","","Mississippi-based Cypress Pharmaceutical Inc., its subsidiary Hawthorn Pharmaceuticals Inc. and its CEO, Max Draughn, have agreed to pay $2.8 million to resolve civil allegations under the False Claims Act, the Justice Department announced. The government alleged that between 2003 and 2009, Cypress, Hawthorn and Draughn were responsible for marketing three pharmaceutical products that were not approved as safe and effective by the Food and Drug Administration (FDA). The products were Hylira, a gel used for the treatment of dry skin, Zaclir, an acne treatment and Zacare, another acne treatment.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil","","","","","","","","","","","","","","","USA","New Jersey","privately held","","","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/mississippi-pharmaceutical-firm-and-ceo-pay-28-million-resolve-allegations-illegal-marketing","",""
"Eisai Inc.","Eisai","Eisai","","$11,000,000","$0","$11,000,000","2010","20101215","healthcare-related offenses","off-label or unapproved promotion of medical products","","Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","Japan","","publicly traded","","JP3160400002","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran","",""
"Elan Corporation PLC","Perrigo","Elan Corp.","Perrigo acquired Elan in 2013.","$203,000,000","$0","$203,000,000","2010","20101215","healthcare-related offenses","off-label or unapproved promotion of medical products","","Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","Ireland","","publicly traded","PRGO","IE00BGH1M568","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran","",""
"Eli Lilly and Company","Eli Lilly","Eli Lilly","","$1,415,000,000","$0","$1,415,000,000","2009","20090115","healthcare-related offenses","off-label or unapproved promotion of medical products","","Eli Lilly and Company agreed to plead guilty and pay $1.415 billion for promoting its drug Zyprexa for uses not approved by the Food and Drug Administration. This resolution included a criminal fine of $515 million, the forfeiture of $100 million in assets, and up to $800 million in a civil settlement with the federal government and the states.","federal","agency action","Justice Department Civil Division","civil and criminal","","","","","","","","","","","","","","","USA","Indiana","publicly traded","LLY","US5324571083","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/eli-lilly-and-company-agrees-pay-1415-billion-resolve-allegations-label-promotion-zyprexa","",""
"Eli Lilly and Company","Eli Lilly","Eli Lilly","","$36,000,000","$0","$36,000,000","2005","20051221","healthcare-related offenses","off-label or unapproved promotion of medical products","","Eli Lilly and Company agreed to plead guilty and to pay $36 million in connection with its illegal promotion of its pharmaceutical drug Evista.","federal","agency action","Justice Department Criminal Division","criminal","","","","","","","","","","","","","","","USA","Indiana","publicly traded","LLY","US5324571083","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/opa/pr/2005/December/05_civ_685.html","",""
"Endo Health Solutions Inc.","Endo International","Endo International","","$192,700,000","$0","$192,700,000","2014","20140221","healthcare-related offenses","off-label or unapproved promotion of medical products","","Pharmaceutical company Endo Health Solutions Inc. and its subsidiary Endo Pharmaceuticals Inc. agreed to pay $192.7 million to resolve criminal and civil liability arising from Endo's marketing of the prescription drug Lidoderm for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a deferred prosecution agreement and forfeiture totaling $20.8 million and civil false claims settlements with the federal government and the states and the District of Columbia totaling $171.9 million. ","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","deferred prosecution agreement","","","","","","","","","","","","","","Ireland","","publicly traded","ENDP","IE00BJ3V9050","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/endo-pharmaceuticals-and-endo-health-solutions-pay-1927-million-resolve-criminal-and-civil","",""
"Ethex Corporation","","","","$27,600,000","$0","$27,600,000","2010","20100302","safety-related offenses","drug or medical equipment safety violation","","Ethex Corporation, a wholly owned subsidiary of St. Louis-based drug manufacturer, KV Pharmaceutical Company, pleaded guilty to two felonies and was sentenced in connection with the manufacturing of oversized prescription drug tablets. The government had charged that, despite having knowledge that the two drugs did not meet required specifications, Ethex violated the law by intentionally withholding this information from the Food and Drug Administration (FDA). Given the seriousness of Ethex's conduct and the risk it posed to consumers of its drugs, the Justice Department pursued felony charges. According to charges presented in U.S. District Court in St. Louis, Ethex failed to submit required ""field alert reports"" to the FDA in 2008 concerning two drugs, propafenone and dextroamphetamine sulfate.  Following the recommendations of a plea agreement, Judge E. Richard Webber sentenced Ethex to pay a fine of more than $23.4 million, pay approximately $2.3 million in restitution to Medicare and Medicaid for their approximate losses, and forfeit nearly $1.8 million to the United States.","federal","agency action","Food and Drug Administration referral to the Justice Department","criminal","","","","","","","","","","","","","","","","","","","","","","http://www.justice.gov/opa/pr/kv-pharmaceutical-subsidiary-pleads-guilty-two-felonies-regarding-oversized-drugs","",""
"Forest Pharmaceuticals Inc.","AbbVie","Forest Laboratories Inc.","Forest Labs was bought by Actavis, which merged with Allergan and both then were bought by AbbVie in 2020","$164,000,000","$0","$164,000,000","2011","20110302","healthcare-related offenses","off-label or unapproved promotion of medical products","","Drug manufacturer Forest Pharmaceuticals Inc. was sentenced by U.S. District Judge Nancy Gertner to pay a criminal fine of $150 million and forfeit assets of $14 million following the company's guilty plea in November 2010 to one felony count of obstructing justice, one misdemeanor count of distributing an unapproved new drug in interstate commerce and one misdemeanor count of distributing a misbranded drug in interstate commerce, the Justice Department announced. The company, a subsidiary of New York City-based Forest Laboratories Inc., pleaded guilty to charges related to obstruction of an FDA regulatory inspection, to the distribution of Levothroid, which at the time was an unapproved new drug, and to the illegal promotion of the anti-depressant drug Celexa for use in treating children and adolescents.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","USA","Illinois","publicly traded","ABBV","US00287Y1091","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/forest-pharmaceuticals-sentenced-pay-164-million-criminal-violations","",""
"Genzyme Corporation","Sanofi","Sanofi","","$32,587,439","$0","$32,587,439","2015","20150903","safety-related offenses","drug or medical equipment safety violation","","Genzyme Corporation, a wholly-owned biotechnology subsidiary of French pharmaceutical company Sanofi, agreed to resolve criminal charges that it violated the federal Food, Drug and Cosmetic Act with regard to the unlawful distribution of Seprafilm, a surgical device it marketed and promoted. As part of the agreed resolution, the department filed a two-count criminal information in the U.S. District Court for the Middle District of Florida charging that between 2005 and 2010, Genzyme caused a medical device to become adulterated and misbranded while being held for sale.  The conduct occurred prior to Sanofi's acquisition of Genzyme, based in Cambridge, Massachusetts, in 2011.  To resolve these charges, Genzyme agreed to enter into a deferred prosecution agreement with the government for a term of at least two years.  As part of the agreement, Genzyme agreed to admit to and accept responsibility for the facts underlying the charges and pay a monetary penalty of $32,587,439.","federal","agency action","Food and Drug Administration referral to the Justice Department","criminal","deferred prosecution agreement","","","","","","","","","","","","","","France","","publicly traded","","FR0000120578","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/genzyme-corporation-pay-325-million-resolve-criminal-liability-relating-seprafilm","",""
"GlaxoSmithKline LLC","GlaxoSmithKline","GlaxoSmithKline","","$3,000,000,000","$0","$3,000,000,000","2012","20120702","healthcare-related offenses","off-label or unapproved promotion of medical products","drug or medical equipment safety violation","Global health care giant GlaxoSmithKline LLC) agreed to plead guilty and to pay $3 billion to resolve its criminal and civil liability arising from the company's unlawful promotion of certain prescription drugs, its failure to report certain safety data, and its civil liability for alleged false price reporting practices. The resolution is the largest health care fraud settlement in U.S. history and the largest payment ever by a drug company.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","United Kingdom","","publicly traded","LSE: GSK","GB0009252882","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/glaxosmithkline-plead-guilty-and-pay-3-billion-resolve-fraud-allegations-and-failure-report","",""
"Globus Medical Inc.","Globus Medical","Globus Medical","","$550,000","$0","$550,000","2012","20120228","healthcare-related offenses","off-label or unapproved promotion of medical products","","Settlement of a civil money penalty action relating to the distribution of unapproved medical devices. Company CEO David C. Paul was required to pay an additional $450,000","federal","agency action","Food and Drug Administration","civil","","","","","","","","","Audubon","Pennsylvania","","","","","USA","Pennsylvania","publicly traded","GMED","US3795772082","medical equipment and supplies","medical equipment","http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm293745.htm","",""
"GNC Holdings Inc.","Harbin Pharmaceutical Group","GNC Holdings","Harbin Pharmaceutical bought GNC in 2020","$2,250,000","$0","$2,250,000","2016","20161207","safety-related offenses","drug or medical equipment safety violation","","GNC Holdings Inc. entered into a wide-ranging agreement with the Department of Justice to reform its practices related to potentially unlawful dietary ingredients and dietary supplements, and has further promised to embark on a series of voluntary initiatives designed to improve the quality and purity of dietary supplements. As part of the agreement, GNC agreed to pay $2.25 million to the U.S. government and cooperate in dietary supplement investigations conducted by the government.","federal","agency action","Food and Drug Administration referral to the Justice Department","criminal","non-prosecution agreement","","","","","","","","","","","","","","China","","government-owned","","","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/gnc-enters-agreement-department-justice-improve-its-practices-and-keep-potentially-illegal","",""
"Google Inc.","Alphabet Inc.","Alphabet Inc.","Alphabet was created as a holding company for Google in 2015","$500,000,000","$0","$500,000,000","2011","20110824","healthcare-related offenses","off-label or unapproved promotion of medical products","","Online search engine Google Inc. agreed to forfeit $500 million for allowing online Canadian pharmacies to place advertisements through its AdWords program targeting consumers in the United States, resulting in the unlawful importation of controlled and non-controlled prescription drugs into the United States.","federal","agency action","Food and Drug Administration referral to the Justice Department","criminal","non-prosecution agreement","","","","","","","","","","","","","","USA","California","publicly traded","Nasdaq: GOOG","US02079K3059","information technology","internet services","https://www.justice.gov/opa/pr/google-forfeits-500-million-generated-online-ads-prescription-drug-sales-canadian-online","",""
"Guidant LLC","Boston Scientific Corp.","Boston Scientific Corp.","","$296,000,000","$0","$296,000,000","2011","20110112","safety-related offenses","drug or medical equipment safety violation","","Guidant LLC, a wholly-owned subsidiary of Boston Scientific Corporation, was formally convicted and sentenced in St. Paul, Minn., before U.S. District Court Judge Donovan W. Frank for criminal violations relating to its interactions with the Food and Drug Administration (FDA). Judge Frank sentenced Guidant to pay more than $296 million in criminal fines and forfeiture and also to submit to the supervision of the U.S. Probation Office for three years. The Justice Department brought criminal charges against Guidant for its mishandling of short-circuiting failures of three models of its implantable cardioverter defibrillators: the Ventak Prizm 2 DR (Model 1861) and the Contak Renewal (Models H135 and H155). Guidant's Cardiac Rhythm Management division, which produced the defibrillators, is headquartered in Arden Hills, Minn. The company pleaded guilty to the charges the previous April.","federal","agency action","Food and Drug Administration referral to the Justice Department","criminal","","","","","","","","","","","","","","","USA","Massachusetts","publicly traded","BSX","US1011371077","medical equipment and supplies","medical devices","http://www.justice.gov/opa/pr/medical-device-manufacturer-guidant-sentenced-failure-report-defibrillator-safety-problems","",""
"Healthpoint Ltd. and DFB Pharmaceuticals","","","","$28,000,000","$0","$28,000,000","2012","20121206","healthcare-related offenses","off-label or unapproved promotion of medical products","kickbacks and bribery","Healthpoint Ltd. and DFB Pharmaceuticals agreed to pay up to $48 million to resolve allegations that Healthpoint caused false claims to be submitted to Medicare and Medicaid for an unapproved drug, Xenaderm, which was ineligible for reimbursement by those programs. Under the terms of the agreement, Healthpoint and DFB agreed to pay $28 million, plus another $20 million if there is a change in ownership of Healthpoint or DFB over the next three years. ","federal","agency action","Food and Drug Administration referral to the Justice Department","civil","","","","","","","","","","","","","","","","","","","","","","https://www.justice.gov/opa/pr/healthpoint-ltd-pay-48-million-false-medicaid-and-medicare-claims-unapproved-prescription","",""
"Johnson & Johnson","Johnson & Johnson","Johnson & Johnson","","$2,200,000,000","$0","$2,200,000,000","2013","20131104","healthcare-related offenses","off-label or unapproved promotion of medical products","kickbacks and bribery","Global health care giant Johnson & Johnson and its subsidiaries agreed to pay more than $2.2 billion to resolve criminal and civil liability arising from allegations relating to the prescription drugs Risperdal, Invega and Natrecor, including promotion for uses not approved as safe and effective by the Food and Drug Administration and payment of kickbacks to physicians and to the nation's largest long-term care pharmacy provider. The global resolution is one of the largest health care fraud settlements in U.S. history, including criminal fines and forfeiture totaling $485 million and civil settlements with the federal government and states totaling $1.72 billion.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","US4781601046","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/johnson-johnson-pay-more-22-billion-resolve-criminal-and-civil-investigations","",""
"Kos Pharmaceuticals","AbbVie","Abbott Laboratories","Kos was part of the spinoff of AbbVie by Abbott in 2013","$41,500,000","$0","$41,500,000","2010","20101207","competition-related offenses","kickbacks and bribery","","Kos Pharmaceuticals, a subsidiary of Abbott Laboratories, agreed to pay more than $41 million to resolve criminal and civil liability arising from allegations that the company offered and paid doctors, other medical professionals, physician groups and managed care organizations illegal kickbacks in the form of money, free travel, grants, honoraria and other valuable goods and services.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","deferred prosecution agreement","","","","","","","","","","","","","","USA","Illinois","publicly traded","ABBV","US00287Y1091","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/kos-pharmaceuticals-pay-more-41-million-resolve-kickback-and-label-promotion-allegations","",""
"McNeil-PPC Inc.","Johnson & Johnson","Johnson & Johnson","","$25,000,000","$0","$25,000,000","2015","20150310","safety-related offenses","drug or medical equipment safety violation","","McNeil-PPC Inc. entered a guilty plea in Federal District Court in Philadelphia to one count of an information charging the company with delivering for introduction into interstate commerce adulterated infants' and childrens' over-the-counter liquid medicines. As part of the criminal resolution, McNeil, a wholly owned subsidiary of Johnson & Johnson, agreed to pay a criminal fine of $20 million and forfeit $5 million.","federal","agency action","Food and Drug Administration referral to the Justice Department","criminal","","","","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","US4781601046","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/mcneil-ppc-inc-pleads-guilty-connection-adulterated-infants-and-childrens-over-counter-liquid","",""
"Medtronic Inc.","Medtronic","Medtronic","","$23,500,000","$0","$23,500,000","2011","20111212","competition-related offenses","kickbacks and bribery","","Medtronic Inc. of Fridley, Minn., agreed to pay $23.5 million to resolve allegations that it violated the False Claim Act by using physician payments related to post-market studies and device registries as kickbacks to induce doctors to implant the company's pacemakers and defibrillators.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil","","","","","","","","","","","","","","","Ireland","","publicly traded","MDT","IE00BTN1Y115","medical equipment and supplies","medical devices","https://www.justice.gov/opa/pr/minnesota-based-medtronic-inc-pays-us-235-million-settle-claims-company-paid-kickbacks","",""
"Merck, Sharp & Dohme","Merck","Merck","","$950,000,000","$0","$950,000,000","2011","20111122","healthcare-related offenses","off-label or unapproved promotion of medical products","","American pharmaceutical company Merck, Sharp & Dohme agreed to pay $950 million to resolve criminal charges and civil claims related to its promotion and marketing of the painkiller Vioxx (rofecoxib). Under the terms of the resolution, Merck agreed to a $628 million civil settlement and the payment of a $322 million criminal fine.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","USA","New Jersey","publicly traded","MRK","US58933Y1055","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/us-pharmaceutical-company-merck-sharp-dohme-pay-nearly-one-billion-dollars-over-promotion","",""
"Novartis Pharmaceuticals Corporation","Novartis","Novartis","","$422,500,000","$0","$422,500,000","2010","20100930","healthcare-related offenses","off-label or unapproved promotion of medical products","","Novartis Pharmaceuticals Corporation agreed to pay $422.5 million to resolve criminal and civil liability arising from the illegal marketing of certain pharmaceutical products. According to the agreement reached with the government, the East Hanover, N.J.-based company was to plead guilty to a misdemeanor and pay a $185 million combined criminal fine and forfeiture for the off-label promotion of Trileptal in violation of the Food, Drug and Cosmetic Act. The Food and Drug Administration (FDA) approved Trileptal as an anti-epileptic drug, for the treatment of partial seizures, but not for any psychiatric, pain or other uses. Once a pharmaceutical is approved by the FDA, a manufacturer may not market or promote it for any use not specified in its new drug application. ","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","Switzerland","","publicly traded","NYSE: NVS","CH0012005267","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/novartis-pharmaceuticals-corp-pay-more-420-million-resolve-label-promotion-and-kickback","",""
"Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation","Novartis","Novartis","","$72,500,000","$0","$72,500,000","2010","20100504","healthcare-related offenses","off-label or unapproved promotion of medical products","False Claims Act and related","Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation agreed to pay $72.5 million to resolve civil False Claims Act allegations arising from the marketing of the cystic fibrosis drug TOBI. The settlement resolved allegations that, between Jan. 1, 2001 and July 31, 2006, Novartis and its predecessor, Chiron Corporation, caused false claims to be submitted to federal health care programs for certain off-label uses of the drug.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil","","","","","","","","","","","","","","","Switzerland","","publicly traded","NYSE: NVS","CH0012005267","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/novartis-vaccines-diagnostics-pay-more-72-million-resolve-false-claims-act-allegations","",""
"Novo Nordisk Inc.","Novo Holdings A/S","Novo Holdings A/S","","$25,000,000","$0","$25,000,000","2011","20110610","healthcare-related offenses","off-label or unapproved promotion of medical products","","Novo Nordisk Inc., a Danish pharmaceutical manufacturer, has agreed to pay $25 million to resolve its civil liability arising from the illegal promotion of its hemostasis management drug, NovoSeven. The Food and Drug Administration (FDA) approved NovoSeven to treat certain bleeding disorders in hemophiliacs.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil","","","","","","","","","","","","","","","Denmark","","privately held","","","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/danish-pharmaceutical-novo-nordisk-pay-25-million-resolve-allegations-label-promotion","",""
"Ortho-McNeil Pharmaceutical LLC","Johnson & Johnson","Johnson & Johnson","","$81,000,000","$0","$81,000,000","2010","20100429","healthcare-related offenses","off-label or unapproved promotion of medical products","","American pharmaceutical manufacturers Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., both subsidiaries of Johnson & Johnson, agreed to pay more than $81 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Topamax.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","US4781601046","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/two-johnson-johnson-subsidiaries-pay-over-81-million-resolve-allegations-label-promotion","",""
"OtisMed Corp.","Stryker","Stryker","","$79,560,000","$0","$79,560,000","2014","20141208","safety-related offenses","drug or medical equipment safety violation","","OtisMed and its CEO Charlie Chi pleaded guilty in federal court in Newark, New Jersey. OtisMed pleaded guilty before U.S. District Judge Claire C. Cecchi to an information charging it with distributing, with the intent to defraud and mislead, adulterated medical devices into interstate commerce in violation of the Food, Drug, and Cosmetic Act. Judge Cecchi fined OtisMed $34.4 million and ordered $5.16 million in criminal forfeiture. In a separate civil settlement, OtisMed agreed to pay $40 million plus interest to resolve its civil liability.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","USA","Michigan","publicly traded","SYK","US8636671013","medical equipment and supplies","medical supplies","http://www.justice.gov/opa/pr/otismed-corporation-and-former-ceo-plead-guilty-distributing-fda-rejected-cutting-guides-knee","",""
"Otsuka American Pharmaceutical Inc.","Otsuka Pharmaceutical","Otsuka Pharmaceutical","","$4,000,000","$0","$4,000,000","2008","20080327","healthcare-related offenses","off-label or unapproved promotion of medical products","False Claims Act and related","Otsuka American Pharmaceutical Inc., the American subsidiary of Japanese pharmaceutical manufacturer Otsuka Pharmaceutical Co., Ltd., agreed to pay over $4 million to resolve allegations of off-label marketing.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","","","","Japan","","publicly traded","","JP3188220002","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/opa/pr/2008/March/08_civ_244.html","",""
"Par Pharmaceutical Companies Inc.","Endo International","Par Pharmaceutical","Endo bought Par in 2015","$45,000,000","$0","$45,000,000","2013","20130305","healthcare-related offenses","off-label or unapproved promotion of medical products","","New Jersey-based Par Pharmaceutical Companies Inc. pleaded guilty in federal court and agreed to pay $45 million to resolve its criminal and civil liability in the company's promotion of its prescription drug Megace ES for uses not approved as safe and effective by the Food and Drug Administration (FDA) and not covered by federal health care programs.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","Ireland","","publicly traded","ENDP","IE00BJ3V9050","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/par-pharmaceuticals-pleads-guilty-and-agrees-pay-45-million-resolve-civil-and-criminal","",""
"Pfizer Inc.","Pfizer","Pfizer","","$2,300,000,000","$0","$2,300,000,000","2009","20090902","healthcare-related offenses","off-label or unapproved promotion of medical products","","American pharmaceutical giant Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc. agreed to pay $2.3 billion to resolve criminal and civil liability arising from the illegal promotion of certain pharmaceutical products. Pfizer was required to pay a criminal fine of $1.195 billion and Pharmacia & Upjohn was required to forfeit $105 million, for a total criminal resolution of $1.3 billion. The other $1 billion represented a civil False Claims Act penalty.","federal","agency action","Justice Department Civil Division","civil and criminal","","","","","","","","","","","","","","","USA","New York","publicly traded","PFE","US7170811035","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history","",""
"Pfizer Inc.","Pfizer","Pfizer","","$55,000,000","$0","$55,000,000","2012","20121212","safety-related offenses","drug or medical equipment safety violation","","Pfizer Inc. agreed to pay $55 million plus interest to resolve allegations that Wyeth LLC illegally introduced and caused the introduction into interstate commerce of a misbranded drug, Protonix, between February 2000 and June 2001.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil","","","","","","","","","","","","","","","USA","New York","publicly traded","PFE","US7170811035","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/pfizer-agrees-pay-55-million-illegally-promoting-protonix-label-use","",""
"Pfizer Inc.","Pfizer","Pfizer","","$14,500,000","$0","$14,500,000","2011","20111021","healthcare-related offenses","off-label or unapproved promotion of medical products","","American pharmaceutical company Pfizer Inc. agreed to pay $14.5 million to resolve False Claims Act allegations related to its marketing of the drug Detrol. The settlement resolved the last of a group of 10 qui tam, or whistleblower, suits that were filed in the District of Massachusetts and two other districts, beginning in 2003. The other nine suits were settled or dismissed in 2009 as part of the government's global resolution with Pfizer, under which the company agreed to pay $2.3 billion dollars to resolve civil claims and criminal charges regarding multiple drugs.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil","","","","","","","","","","","","","","","USA","New York","publicly traded","PFE","US7170811035","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/pfizer-pay-145-million-illegal-marketing-drug-detrol","",""
"Quality Egg LLC","Quality Egg","Quality Egg","","$6,790,000","$0","$6,790,000","2015","20150413","safety-related offenses","food safety violation","","The company owner, a top executive and their company, Quality Egg LLC, were sentenced in federal district court in Sioux City, Iowa in connection with the distribution of adulterated eggs. Austin ""Jack"" DeCoster, 81, of Turner, Maine, who owned Quality Egg, was sentenced to serve three months in prison to be followed by one year of supervised release, and fined $100,000.  His son, Peter DeCoster, 51, of Clarion, Iowa, who was Quality Egg's chief operating officer, was also sentenced to serve three months in prison to be followed by one year of supervised release, and fined $100,000.  Quality Egg was sentenced to pay a fine of $6.79 million and placed on probation for three years.  All three defendants were ordered to make restitution in the total amount of $83,008.19.  Quality Egg also agreed to forfeit $10,000 as part of its plea agreement with the government. ","federal","agency action","Food and Drug Administration referral to the Justice Department","civil","","","","","","","","","","","","","","","USA","Maine","privately held","","","food products","food products","http://www.justice.gov/opa/pr/quality-egg-company-owner-and-top-executive-sentenced-connection-distribution-adulterated","",""
"Ranbaxy USA Inc.","Sun Pharmaceuticals","Daiichi Sankyo","Sun bought Ranbaxy in 2015","$500,000,000","$0","$500,000,000","2013","20130513","safety-related offenses","drug or medical equipment safety violation","","In the largest drug safety settlement to date with a generic drug manufacturer, Ranbaxy USA Inc. , a subsidiary of Indian generic pharmaceutical manufacturer Ranbaxy Laboratories Limited, pleaded guilty to felony charges relating to the manufacture and distribution of certain adulterated drugs made at two of Ranbaxy's manufacturing facilities in India. Ranbaxy also agreed to pay a criminal fine and forfeiture totaling $150 million and to settle civil claims under the False Claims Act and related State laws for $350 million.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","India","","publicly traded","","INE044A01036","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/generic-drug-manufacturer-ranbaxy-pleads-guilty-and-agrees-pay-500-million-resolve-false","",""
"Roos Foods Inc.","","","","$100,000","$0","$100,000","2016","20160303","safety-related offenses","food safety violation","","Roos Foods Inc., a Delaware company, pleaded guilty to a misdemeanor violation of the Federal Food, Drug and Cosmetic Act in the U.S. District Court for the District of Delaware. U.S. Magistrate Judge Sherry R. Fallon accepted the company's guilty plea and sentenced Roos Foods to pay a fine of $100,000.","federal","agency action","Food and Drug Administration","criminal","","","","","","","","","","","","","","","","","","","","","","https://www.justice.gov/opa/pr/delaware-cheese-company-pleads-guilty-food-adulteration-charge","",""
"SB Pharmco Puerto Rico Inc.","GlaxoSmithKline","GlaxoSmithKline","","$750,000,000","$0","$750,000,000","2010","20101026","safety-related offenses","drug or medical equipment safety violation","","SB Pharmco Puerto Rico Inc., a subsidiary of GlaxoSmithKline, PLC, agreed to plead guilty to charges relating to the manufacture and distribution of certain adulterated drugs made at GSK's now-closed Cidra, Puerto Rico, manufacturing facility. The resolution included a criminal fine and forfeiture totaling $150 million and a civil settlement under the False Claims Act and related state claims for $600 million.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","United Kingdom","","publicly traded","LSE: GSK","GB0009252882","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/glaxosmithkline-plead-guilty-pay-750-million-resolve-criminal-and-civil-liability-regarding","",""
"Scios Inc.","Johnson & Johnson","Johnson & Johnson","","$85,000,000","$0","$85,000,000","2011","20111005","healthcare-related offenses","off-label or unapproved promotion of medical products","","Scios Inc., a subsidiary of pharmaceutical giant Johnson & Johnson, pleaded guilty to a misdemeanor violation of the Food, Drug and Cosmetic Act for introducing into interstate commerce its heart failure drug, Natrecor, for a use that was not approved by the Food and Drug Administration, the Justice Department announced. The district court also sentenced Scios, based in Fremont, Calif., to pay an $85 million criminal fine in accordance with the plea agreement between Scios and the United States.","federal","agency action","Food and Drug Administration referral to the Justice Department","criminal","","","","","","","","","","","","","","","USA","New Jersey","publicly traded","JNJ","US4781601046","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/johnson-johnson-subsidiary-scios-pleads-guilty-misbranding-heart-failure-drug-natrecor","",""
"SCM True Air Technologies, Inc.","","","","$711,691","$0","$711,691","2017","20170418","safety-related offenses","drug or medical equipment safety violation","","SCM True Air Technologies, Inc. pled guilty to one count of operating an establishment that manufactured medical devices without having properly registered that establishment as required by law.","federal","agency action","Food and Drug Administration","criminal","","","","","","","","","","","","","","","","","","","","","","https://www.fda.gov/ICECI/CriminalInvestigations/ucm553739.htm","",""
"Serono, S.A.","Merck KGaA (EMD)","Serono","Merck acquired Sorono in 2006","$704,000,000","$0","$704,000,000","2005","20051017","healthcare-related offenses","off-label or unapproved promotion of medical products","False Claims Act and related","Swiss corporation, Serono, S.A., together with its U.S. subsidiaries and related entities, agreed to pay $704 million to resolve criminal charges and civil allegations in connection with illegal schemes to promote, market and sell its drug Serostim used to treat AIDS wasting, a condition involving profound involuntary weight loss in AIDS patients.","federal","agency action","Justice Department Civil Division","civil and criminal","","","","","","","","","","","","","","","Germany","","publicly traded","","DE0006599905","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/opa/pr/2005/October/05_civ_545.html","",""
"Shire Pharmaceuticals LLC","Takeda Pharmaceutical","Shire plc","Shire was acquired by Takeda in 2019.","$56,500,000","$0","$56,500,000","2014","20140924","healthcare-related offenses","off-label or unapproved promotion of medical products","False Claims Act and related","Shire Pharmaceuticals LLC agreed to pay $56.5 million to resolve civil allegations that it violated the False Claims Act as a result of its marketing and promotion of several drugs for certain uses despite a lack of clinical data to support such claims and overstated the efficacy of the drugs.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil","","","","","","","","","","","","","","","Japan","","publicly traded","","JP3463000004","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/shire-pharmaceuticals-llc-pay-565-million-resolve-false-claims-act-allegations-relating-drug","",""
"Spectranetics Corporation","Royal Philips","Spectranetics","Philips acquired Spectranetics in 2017","$5,000,000","$0","$5,000,000","2009","20091229","healthcare-related offenses","off-label or unapproved promotion of medical products","drug or medical equipment safety violation","Spectranetics Corporation, a medical device manufacturer, agreed to pay the United States $4.9 million in civil damages plus a $100,000 forfeiture to resolve claims against the company arising from allegations that the company illegally imported unapproved medical devices and provided them to physicians for use in patients, conducted a clinical study in a manner that failed to comply with federal regulations and promoted certain products for procedures for which the company had not received Food and Drug Administration approval or clearance.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","","","","Netherlands","","publicly traded","","NL0000009538","diversified","diversified","https://www.justice.gov/opa/pr/colorado-based-spectranetics-corporation-pay-5-million-resolve-allegations-relating-its","",""
"True World Foods Chicago, LLC","","","","$60,000","$0","$60,000","2008","20080312","environment-related offenses","environmental violation","","True World Foods Chicago, LLC, was sentenced to pay $60,000 for its role in purchasing and re-selling falsely labeled frozen fish fillets in violation of the Lacey Act.","federal","agency action","Justice Department Environment and Natural Resources Division","criminal","","","","","","","","","","","","","","","","","","","","","","https://www.justice.gov/archive/opa/pr/2008/March/08_enrd_199.html","",""
"UCB Inc.","UCB","UCB","","$34,000,000","$0","$34,000,000","2011","20110609","healthcare-related offenses","off-label or unapproved promotion of medical products","","The U.S. subsidiary of Belgian pharmaceutical manufacturer UCB SA. pleaded guilty to the off-label promotion of its epilepsy drug Keppra and will pay more than $34 million to resolve criminal and civil liability arising out of its illegal conduct.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","Belgium","","publicly traded","","BE0003739530","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/us-subsidiary-belgian-pharmaceutical-manufacturer-pleads-guilty-label-promotion-company-pay","",""
"Warner Chilcott PLC","AbbVie","Actavis PLC","Actavis merged with Allergan and both then were bought by AbbVie in 2020","$125,000,000","$0","$125,000,000","2015","20151029","healthcare-related offenses","off-label or unapproved promotion of medical products","","Warner Chilcott U.S. Sales LLC, a subsidiary of pharmaceutical manufacturer Warner Chilcott PLC, agreed to plead guilty to a felony charge of health care fraud. The plea agreement was part of a global settlement with the United States in which Warner Chilcott agreed to pay $125 million to resolve its criminal and civil liability arising from the company's allegedly illegal marketing of the drugs Actonel, Asacol, Atelvia, Doryx, Enablex, Estrace and Loestrin.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","USA","Illinois","publicly traded","ABBV","US00287Y1091","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/warner-chilcott-agrees-plead-guilty-felony-health-care-fraud-scheme-and-pay-125-million","",""
"Warner-Lambert","Pfizer","Pfizer","","$430,000,000","$0","$430,000,000","2004","20040513","healthcare-related offenses","off-label or unapproved promotion of medical products","kickbacks and bribery","Warner-Lambert agreed to plead guilty and pay more than $430 million to resolve criminal charges and civil liabilities in connection with its Parke-Davis division's allegedly  illegal and fraudulent promotion of unapproved uses for one of its Neurontin anti-seizure drug.","federal","agency action","Justice Department Civil Division","civil and criminal","","","","","","","","","","","","","","","USA","New York","publicly traded","PFE","US7170811035","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/opa/pr/2004/May/04_civ_322.htm","",""
"Wyeth Pharmaceuticals Inc.","Pfizer","Pfizer","","$490,900,000","$0","$490,900,000","2013","20130730","healthcare-related offenses","off-label or unapproved promotion of medical products","","Wyeth Pharmaceuticals Inc., a pharmaceutical company acquired by Pfizer, Inc. in 2009, has agreed to pay $490.9 million to resolve its criminal and civil liability arising from the unlawful marketing of the prescription drug Rapamune for uses not approved as safe and effective by the U.S. Food and Drug Administration.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","","","","USA","New York","publicly traded","PFE","US7170811035","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/wyeth-pharmaceuticals-agrees-pay-4909-million-marketing-prescription-drug-rapamune-unapproved","",""
"InterMune Inc.","Roche","InterMune","Roche acquired InterMune in 2014.","$36,900,000","$0","$36,900,000","2006","20061026","healthcare-related offenses","off-label or unapproved promotion of medical products","","InterMune, Inc, a Brisbane, Cal., biopharmaceutical company, agreed to pay the United States more than $36.9 million to resolve criminal charges and civil liabilities in connection with its alleged illegal promotion and marketing of Actimmune.","federal","agency action","Justice Department Civil Division","civil and criminal","deferred prosecution agreement","","","","","","","","","","","","","","Switzerland","","publicly traded","","CH0012032048","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/opa/pr/2006/October/06_civ_728.html","",""
"Wyeth-Ayerst Laboratories Division","Pfizer","Wyeth","Pfizer bought Wyeth in 2009","$30,000,000","$0","$30,000,000","2000","20001003","safety-related offenses","drug or medical equipment safety violation","","The Food and Drug Administration announced that Wyeth-Ayerst Laboratories Division of American Home Products Corporation and Wyeth- Ayerst Pharmaceuticals, Inc. signed a consent decree of permanent injunction in which Wyeth agreed to a series of measures aimed at ensuring that the products manufactured at Wyeth's Marietta, Pa. and Pearl River, N.Y. facilities are made in compliance with FDA's good manufacturing practice regulations.","federal","agency action","Food and Drug Administration","civil","","","","","","","","","","","","","","","USA","New York","publicly traded","PFE","US7170811035","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20001219083500/http://www.fda.gov/bbs/topics/ANSWERS/ANS01041.html","",""
